Our Journey

Take a look at our journey of creating the first comprehensive AI diagnostic solutions.

Mediwhale’s most defining moments

2022

August

Reti-CVD was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea

June

Reti-Eye was installed in Cheonho public health clinic in Seoul as part of a metabolic disease prevention campaign

April

“Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk” was published in the peer-reviewed medical journal, Age and Ageing (IF:12.8)

Reti-Eye & Reti-CVD were registered as class IIa medical devices by the National Agency of Drug and Food Control (NA-DFC) of Indonesia – Category: Cardiovascular risk assessment based on retinal image & eye screening service

February

Singapore office was opened

Reti-Eye & Reti-CVD were registered as a medical device by Medicines and Healthcare products Regulatory Agency of UK – Category: Cardiovascular risk assessment based on retinal image & eye screening service

January

Reti-Eye was registered as a medical device by the Health Science Authority (HSA) of Singapore – Category: Cardiovascular risk assessment based on retinal image & eye screening service

2021

December

Reti-Eye & Reti-CVD were registered as a class IIa medical device by the Australian Registry of Therapeutic Goods (ARTG)

Reti-Eye & Reti-CVD were registered as class B medical devices by Health Sciences Authority (HSA) of Singapore

October

Reti-Eye & Reti-CVD were registered as class B medical devices by the Ministry of Health of Malaysia

August

A patent “AI technology that predicts cardiovascular disease risk through retinal image” was transferred from Singapore Eye Center

May

Reti-Eye & Reti-CVD obtained CE approval as a class IIa medical device in the EU – Category: Cardiovascular risk assessment based on retinal image & eye screening service

“Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs” was published in a top-tier medical journal (The Lancet Digital Health, IF:36.6)

2020

December

Reti-CVD was registered as an innovative medical device by the Ministry of Food and Drug Safety of Korea for screening cardiovascular risk

November

Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms” was published in a top-tier medical journal (The Lancet Digital Health, IF: 36.6)

August

Reti-Eye was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea  

May

 ISO 13485 certification was obtained

2019

July

 A research collaboration agreement was signed with Singapore Eye Research Institute (SERI)

March

KGMP (Korean Good Manufacturing Practice) certificate was obtained

February

8 patented technologies were transferred from Yonsei University including “Retinal image analysis method” and “Cardiovascular disease diagnosis through retinal image”

2018

August

A research collaboration agreement was signed with Yonsei University Health System to develop AI-based eye screening technology through retinal image analysis

March

“Retinal image analysis method” technologies were transferred from Yonsei University

2017

September

A leadership team of Kevin Taegeun Choi, Tyler Hyungtaek Rim, and Young Geunyoung Lee was formed

MAR

2nd place was awarded in the biggest medical data analysis competition hosted by Asan Medical Center & Microsoft Korea

2016

December

Mediwhale Inc. was founded in Seoul, Korea